Pharma Cos. Get Cert. In MDL Over Generic Prograf Delays

Law360, New York (April 24, 2013, 6:05 PM EDT) -- A Massachusetts federal judge on Tuesday certified a class of pharmaceutical companies in multidistrict antitrust litigation that accuses Astellas Pharma US Inc. of keeping a generic version of its immunosuppressant Prograf off the market, forcing the plaintiffs to pay higher prices for the drug. 

The class is limited to individuals or entities who purchased Prograf directly from Astellas between April 2008 and December 2011, according to the order filed in the U.S. District Court for the District of Massachusetts. Judge Rya Zobel ruled that the antitrust...
To view the full article, register now.